108 related articles for article (PubMed ID: 7830119)
21. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.
Reske SN; Grillenberger KG; Glatting G; Port M; Hildebrandt M; Gansauge F; Beger HG
J Nucl Med; 1997 Sep; 38(9):1344-8. PubMed ID: 9293784
[TBL] [Abstract][Full Text] [Related]
22. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.
Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF
Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396
[TBL] [Abstract][Full Text] [Related]
23. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
[TBL] [Abstract][Full Text] [Related]
24. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.
Higashi T; Tamaki N; Honda T; Torizuka T; Kimura T; Inokuma T; Ohshio G; Hosotani R; Imamura M; Konishi J
J Nucl Med; 1997 Sep; 38(9):1337-44. PubMed ID: 9293783
[TBL] [Abstract][Full Text] [Related]
25. [Tumor diagnosis using 18F-FDG SPECT].
Sugiyama S; Suzuki Y; Matsuzaki H; Tomiyoshi K; Endo K
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Aug; 56(9):679-80. PubMed ID: 8831228
[TBL] [Abstract][Full Text] [Related]
26. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
Torizuka T; Tamaki N; Inokuma T; Magata Y; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
J Nucl Med; 1994 Dec; 35(12):1965-9. PubMed ID: 7989978
[TBL] [Abstract][Full Text] [Related]
27. Persistent twenty-four hour SPECT thallium-201 defects, plasma thallium-201 concentrations and PET metabolic viability.
Brunken RC; Mody FV; Hawkins RA; Nienaber CA; Phelps ME; Schelbert HR
Herz; 1994 Feb; 19(1):28-41. PubMed ID: 8150412
[TBL] [Abstract][Full Text] [Related]
28. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
[TBL] [Abstract][Full Text] [Related]
29. The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy.
Lorberboym M; Mandell LR; Mosesson RE; Germano I; Lou W; DaCosta M; Linzer DG; Machac J
J Nucl Med; 1997 Feb; 38(2):223-6. PubMed ID: 9025741
[TBL] [Abstract][Full Text] [Related]
30. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.
Kato T; Fukatsu H; Ito K; Tadokoro M; Ota T; Ikeda M; Isomura T; Ito S; Nishino M; Ishigaki T
Eur J Nucl Med; 1995 Jan; 22(1):32-9. PubMed ID: 7698152
[TBL] [Abstract][Full Text] [Related]
31. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma.
Nakata B; Chung YS; Nishimura S; Nishihara T; Sakurai Y; Sawada T; Okamura T; Kawabe J; Ochi H; Sowa M
Cancer; 1997 Feb; 79(4):695-9. PubMed ID: 9024707
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET evaluation of indeterminate pancreatic masses.
Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
[TBL] [Abstract][Full Text] [Related]
33. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
34. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
Lowe VJ; DeLong DM; Hoffman JM; Coleman RE
J Nucl Med; 1995 May; 36(5):883-7. PubMed ID: 7738668
[TBL] [Abstract][Full Text] [Related]
35. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
36. Rest distribution of 99mTc-MIBI in patients with coronary artery disease assessed by SPECT: comparison with the distribution of [18F]FDG assessed by PET.
Gang H; Lucignani G; Landoni C; Galli L; Vanoli G; Rossetti C; Paganelli G; Fazio F
J Nucl Biol Med (1991); 1994 Dec; 38(4):540-4. PubMed ID: 7786915
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results.
Bares R; Klever P; Hellwig D; Hauptmann S; Fass J; Hambuechen U; Zopp L; Mueller B; Buell U; Schumpelick V
Nucl Med Commun; 1993 Jul; 14(7):596-601. PubMed ID: 8355920
[TBL] [Abstract][Full Text] [Related]
38. Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera.
Sandler MP; Bax JJ; Patton JA; Visser FC; Martin WH; Wijns W
J Nucl Med; 1998 Dec; 39(12):2035-43. PubMed ID: 9867138
[TBL] [Abstract][Full Text] [Related]
39. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer.
Kosuda S; Kison PV; Greenough R; Grossman HB; Wahl RL
Eur J Nucl Med; 1997 Jun; 24(6):615-20. PubMed ID: 9169567
[TBL] [Abstract][Full Text] [Related]
40. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities.
Lowe VJ; Hoffman JM; DeLong DM; Patz EF; Coleman RE
J Nucl Med; 1994 Nov; 35(11):1771-6. PubMed ID: 7965154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
